Edson Duarte Moreira1, Anna R Giuliano2, Joel Palefsky3, Carlos Aranda Flores4, Stephen Goldstone5, Daron Ferris6, Richard J Hillman7, Harald Moi8, Mark H Stoler9, Brooke Marshall10, Scott Vuocolo10, Dalya Guris10, Richard M Haupt10. 1. Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia. 2. Center for Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 3. Department of Medicine, University of California-San Francisco. 4. University Medical Center, National Public Health Institute, Morelos, Mexico. 5. Mount Sinai School of Medicine, New York, New York. 6. Gynecologic Cancer Prevention Center, Georgia Health Sciences University, Augusta. 7. Western Sydney Sexual Health Centre, University of Sydney, Australia. 8. Olafia STI Clinic, Oslo University Hospital, University of Oslo, Norway. 9. University of Virginia, Charlottesville. 10. Merck, North Wales, Pennsylvania.
Abstract
BACKGROUND: In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. METHODS: A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, Latin America, and North America. Subjects underwent anogenital examinations and sampling of the penis, scrotum, and perineal/perianal regions. RESULTS: The incidence rate of any HPV DNA genotype 6, 11, 16, and/or 18 detection was 9.0 cases per 100 person-years. Rates of HPV DNA detection were highest in men from Africa. Median time to clearance of HPV genotypes 6, 11, 16, and 18 DNA was 6.1, 6.1, 7.7, and 6.2 months, respectively. Median time to clearance of persistently detected HPV 6, 11, 16, and 18 DNA was 6.7, 3.2, 9.2, and 4.7 months, respectively. CONCLUSION: The study results suggest that the acquisition of HPV 6, 11, 16, and/or 18 in males is common and that many of these so-called infections are subsequently cleared, similar to findings for women. Nevertheless, given the high rate of HPV detection among young men, HPV vaccination of males may reduce infection in men and reduce the overall burden of HPV-associated disease in the community.
BACKGROUND: In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. METHODS: A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, Latin America, and North America. Subjects underwent anogenital examinations and sampling of the penis, scrotum, and perineal/perianal regions. RESULTS: The incidence rate of any HPV DNA genotype 6, 11, 16, and/or 18 detection was 9.0 cases per 100 person-years. Rates of HPV DNA detection were highest in men from Africa. Median time to clearance of HPV genotypes 6, 11, 16, and 18 DNA was 6.1, 6.1, 7.7, and 6.2 months, respectively. Median time to clearance of persistently detected HPV 6, 11, 16, and 18 DNA was 6.7, 3.2, 9.2, and 4.7 months, respectively. CONCLUSION: The study results suggest that the acquisition of HPV 6, 11, 16, and/or 18 in males is common and that many of these so-called infections are subsequently cleared, similar to findings for women. Nevertheless, given the high rate of HPV detection among young men, HPV vaccination of males may reduce infection in men and reduce the overall burden of HPV-associated disease in the community.
Authors: Staci L Sudenga; Donna J Ingles; Christine M Pierce Campbell; Hui-Yi Lin; William J Fulp; Jane L Messina; Mark H Stoler; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: Eur Urol Date: 2015-06-06 Impact factor: 20.096
Authors: Emmanuel Chandler; Lili Ding; Pamina Gorbach; Eduardo L Franco; Darron A Brown; Lea E Widdice; David I Bernstein; Jessica A Kahn Journal: J Adolesc Health Date: 2018-07 Impact factor: 5.012
Authors: Enklajd Marsela; Angelika J Fischbeck; Johannes A Hildebrand; Rui Aoki; Lars E French; Andreas Wollenberg; Elisa Schmoeckel; Markus Reinholz Journal: Acta Derm Venereol Date: 2020-02-25 Impact factor: 3.875